# A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

> **NCT03690154** · PHASE1 · TERMINATED · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 67 (actual)

## Conditions studied

- Advanced Cancer
- Solid Tumors
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse

## Interventions

- **DRUG:** FN-1501

## Key facts

- **NCT ID:** NCT03690154
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-23
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-02-11
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Despite demonstrated safety and tolerability the trial was terminated early due to program re-prioritization in light of the competitive landscape.
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690154, "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03690154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*